Mirati Therapeutics

What Mirati Therapeutics does

Mirati Therapeutics is a San Diego, California-based biopharmaceutical company founded in 1995 that develops targeted small-molecule oncology therapies, with a domain specialization in KRAS-mutated cancers that were historically considered undruggable. Its lead asset is Adagrasib (marketed as Krazati), an FDA-approved KRAS G12C inhibitor indicated for KRAS G12C-mutated non-small cell lung cancer and pancreatic cancer; the broader pipeline included an early-phase SOS1 inhibitor program targeting the RAS pathway for combination use (later removed from the Bristol Myers Squibb pipeline in October 2025).

The company historically generated revenue via traditional biopharmaceutical commercialization of its approved oncology product through specialty pharmacy, hospital formulary, and oncology treatment center channels, following FDA approval. It served oncologists, healthcare providers, and KRAS G12C-mutated cancer patients, particularly those with pancreatic cancer and non-small cell lung cancer, addressing high unmet medical need. Capital was raised primarily through public equity offerings post-IPO on NASDAQ under ticker MRTX, including a $500 million offering in November 2021 and an upsized $345 million offering in August 2023.

In January 2024, Bristol Myers Squibb acquired Mirati Therapeutics for $4.8 billion as a strategic move to bolster its oncology portfolio and offset upcoming patent cliffs on blockbuster drugs such as Revlimid and Eliquis. Mirati now operates as a wholly-owned subsidiary of BMS, with its assets (including Krazati) integrated into BMS's broader oncology franchise. Prior to the acquisition, leadership included CEO and President Charles M. Baum, Chief Scientific Officer James Christensen, COO Daniel Faga, and director-level logistics head Kevin Hickman.

Name

Mirati Therapeutics

Legal name

Mirati Therapeutics, Inc.

Website

https://mirati.com

Company type

Private

Founded year

1995

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Mirati Therapeutics is a San Diego-based biopharmaceutical company that develops targeted small-molecule oncology therapies, most notably the FDA-approved KRAS G12C inhibitor Krazati (adagrasib) for non-small cell lung cancer and pancreatic cancer. Acquired by Bristol Myers Squibb for $4.8 billion in January 2024.

Ownership category

akta.pro rank

Product category

Targeted Oncology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industry

Gastrointestinal Oncology (HLAKAFAK)

Keywords

• Targeted oncology therapeutics
• KRAS inhibitor drugs
• Precision cancer medicine
• Small molecule oncology
• Biopharmaceutical drug development

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

Mirati Therapeutics develops and commercializes targeted oncology therapies, with its lead product Krazati (adagrasib), an FDA-approved KRAS G12C inhibitor for the treatment of KRAS G12C-mutated non-small cell lung cancer and pancreatic cancer. The company also pursued a pipeline of small molecule targeted therapies, including a SOS1 inhibitor program targeting RAS pathway signaling, designed to address historically undruggable oncogenic mutations. Products were distributed through specialty pharmacies, hospital formularies, and oncology treatment centers following FDA approval.

Differentiator

Problem solved

Functional benefit

Products and services

• Krazati (adagrasib) Adagrasib, marketed as Krazati, is a KRAS G12C inhibitor indicated for the treatment of KRAS G12C-mutated cancers, including non-small cell lung cancer and pancreatic cancer, providing a targeted therapeutic option for patients with these specific oncogenic mutations.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Bristol Myers SquibbcoreStrategic or Co-development Partner · 1 January 2024Bristol Myers Squibb acquired Mirati Therapeutics for $4.8 billion in January 2024 to strengthen its oncology portfolio, acquiring Krazati (adagrasib) and the broader pipeline including a SOS1 inhibitor program. The acquisition was part of BMS's strategy to address patent cliff challenges and expand its growth portfolio in oncology, particularly pancreatic cancer treatment.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Erasca: Erasca is a precision oncology company focused on the MAPK pathway with multiple KRAS and downstream inhibitor programs, overlapping directly with Mirati's RAS-pathway targeting approach.
• Amgen: Amgen developed sotorasib (Lumakras), the first FDA-approved KRAS G12C inhibitor, directly competing with Mirati's Krazati in KRAS G12C-mutated NSCLC and across combination-therapy development.
• Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing a broad portfolio of RAS-targeted inhibitors including KRAS G12C, G12D, and pan-RAS assets, directly overlapping Mirati's RAS-pathway strategy.

Broad incumbents

• Pfizer: Pfizer is a global oncology incumbent with a broad targeted-therapy and combination pipeline that overlaps Mirati's KRAS franchise, particularly through PD-1/PD-L1 combination opportunities.
• AstraZeneca: AstraZeneca is a global oncology incumbent developing KRAS G12D inhibitors and a broad targeted-oncology pipeline, competing with Mirati's assets as part of a much larger commercial portfolio.
• Merck & Co. Merck is a global oncology leader combining Keytruda (PD-1) leadership with a targeted-therapy pipeline that intersects Mirati's KRAS franchise, particularly in combination therapy settings.
• Genentech (Roche): Genentech/Roche is a major oncology incumbent with a broad targeted-therapy pipeline including KRAS and MAPK-pathway assets, providing indirect competition across indications Mirati serves.
• Bristol Myers Squibb: BMS acquired Mirati in January 2024 for $4.8B and now owns Krazati; it is the parent oncology incumbent with deep I-O combinations (Opdivo, Yervoy) that shape Mirati's commercial and clinical trajectory.

Emerging players

• BeiGene: BeiGene is a global oncology biotech with a growing targeted-therapy pipeline and strong commercialization capabilities, making it an emerging peer in precision oncology where Mirati competed.
• Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology biotech developing small molecule therapies against allosteric oncogenic mutations, sharing Mirati's targeted-kinase approach but with a broader mutation-agnostic platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/miratitx
• Facebookfacebook.com/miratitx
• LinkedInlinkedin.com/company/mirati-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirati Therapeutics